| Drug Type Recombinant protein | 
| Synonyms CT-400 (Creabilis Therapeutics), CT-500 | 
| Target | 
| Action inhibitors | 
| Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedDiscovery | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Autoimmune Diseases | Discovery | France  | - | |
| Autoimmune Diseases | Discovery | Italy  | - | |
| Cardiovascular Diseases | Discovery | France  | - | |
| Cardiovascular Diseases | Discovery | Italy  | - | |
| Infectious Diseases | Discovery | France  | - | |
| Neoplasms | Discovery | France  | - | |
| Neoplasms | Discovery | Italy  | - | |
| Nervous System Diseases | Discovery | France  | - | |
| Nervous System Diseases | Discovery | Italy  | - | |
| Sepsis | Discovery | Italy  | - | 






